Abstract LB042: A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4

Background Rhabdomyosarcoma (RMS) is the most common pediatric sarcoma, representing 3-4% of childhood and adolescent cancers. Although multimodal therapies have significantly improved the overall survival of patients with localized disease, 5-year overall survival for patients with relapsed and met...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 84; no. 7_Supplement; p. LB042
Main Authors Tian, Meijie, Jia, Katrina, Wu, Jerry T., Wei, Jun S., Cheuk, Adam T., Zhang, Zhongmei, Pope, Eleanor G., Shor, Boris, Tumey, L. Nathan, Khan, Javed
Format Journal Article
LanguageEnglish
Published 05.04.2024
Online AccessGet full text
ISSN1538-7445
1538-7445
DOI10.1158/1538-7445.AM2024-LB042

Cover